James M Foran
41PUBLICATIONS
161CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (41)
Sort by Publication Date:
|Apr 06, 2026
CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients.Saubia Fathima, Lior Rokach, Nour Ghosoun
|Mar 30, 2026
Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex.Nancy Gillis, Christelle Colin-Leitzinger, Yi-Han Tang
|Mar 18, 2026
Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis From the Multicenter, Open-Label, Phase 2 Study (REFINE).Francesco Passamonti, James M Foran, Anand Tandra
|Feb 25, 2026
Distinct advantages for risk scoring models in patients with clonal cytopenia of undetermined significance.Yazan Jabban, Rong He, Kurt Bessonen
|Feb 18, 2026
TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast-Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent.Naseema Gangat, Momna Warraich, Sudhesh Kumar
Pageof 7
Frequent Collaborators
17 joint publications
Naseema Gangat
16 joint publications
Talha Badar
13 joint publications
Aref Al-Kali
13 joint publications
Mithun Vinod Shah
13 joint publications
Ayalew Tefferi
12 joint publications
Hassan B Alkhateeb
12 joint publications
Abishek A Mangaonkar
11 joint publications
Mrinal Patnaik
10 joint publications
William J Hogan
10 joint publications
Mark R Litzow